Showing pharmacokinetics for Trans-Resveratrol metabolite after consumption of various sources

Asensi M., Medina I., Ortega A., Carretero J., Bano M.C., Obrador E., Estrela J.M. (2002) Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 33:387-98 PubMed (15736313)

Plasma analysed without enzymatic deconjugation

Plasma Concentration (µmol/L)
Number	Dose	Multiple Dose Duration	Time (minutes)						Polyphenol Source Name as described in publication
			0	2.5	5	10	30	60
1	20 mg/kg bw	Single Dose	0	1.1	0.7	0.3	0.07	0.03	trans-resveratrol
2	20 mg/kg bw	Single Dose	0	0.7	1.2	0.4	0.1	0.07	trans-resveratrol
3	20 mg/kg bw	Single Dose	0	2.6	1.7	0.2	0.04	0.02	trans-resveratrol

L)&chxp=1,50|3,50&chd=t:0.0,2.5,5.0,10.0,30.0,60.0|0.0,1.1,0.7,0.3,0.07,0.03|0.0,2.5,5.0,10.0,30.0,60.0|0.0,0.7,1.2,0.4,0.1,0.07|0.0,2.5,5.0,10.0,30.0,60.0|0.0,2.6,1.7,0.2,0.04,0

Showing pharmacokinetics for Trans-Resveratrol metabolite after consumption of various sources Metabolism

Plasma analysed without enzymatic deconjugation